For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA HD and EYLEA. Regeneron (NASDAQ: REGN) is a leading biotechnology company that ...

Image Source: Zacks Investment Research Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product. The two studies ...

boosted by strong demand for a new formulation of its blockbuster eye drug Eylea. The company also announced a new quarterly cash dividend and boosted its share-buyback program by $3 billion ...

Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...

Eylea HD results were consistent across patients with branch RVOs and those with central retinal or hemiretinal vein occlusions. In the past three months, shares of REGN have plunged 35.7% ...

As the company faces increasing competition for its flagship product Eylea, it continues to leverage its strong research and development capabilities to expand its pipeline and explore new growth ...

Flattening sales in the Eylea ophthalmology franchise were more than offset by strong sales from immunology drug Dupixent and oncology drug Libtayo. Despite strong competitive pressures facing the ...

The European Commission's decision on approval is expected in the second half of January 2025. Eylea is used to treat neovascular age-related macular degeneration and other severe retinal diseases.